CyPass® Micro-Stent

Reflecting its uncompromising commitment to patient safety, Alcon announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent...

News Hour: Alcon, the global leader in eye care and a division of Novartis, announced the EU launch of the CyPass® Micro-Stent, a micro-invasive glaucoma surgical (MIGS) device, indicated for the treatment of patients with mild...

News Hour: Alcon, the global leader in eye care and a division of Novartis, announced today that it has achieved FDA approval for the CyPass® Micro-Stent, a micro-invasive glaucoma surgical (MIGS) device to treat patients with...